ArticleBlood cancer journal2026
Development and multinational validation of a multiple myeloma-specific comorbidity index using real-world cohorts: CAREMM-2108.
Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundFrailty and comorbidity substantially influence clinical outcomes in patients with multiple myeloma (MM), yet existing tools such as the IMWG frailty score and Charlson Comorbidity Index (CCI) have limitations in real-world applicability and disease specificity.
objectiveTo develop and externally validate a multiple myeloma-specific comorbidity index (MM-CI) using real-world data from Korean and Japanese cohorts. MATERIALS AND
methodsThis retrospective study was conducted in two parts: (I) development of MM-CI using a nationwide Korean claims cohort of 17,273 MM patients diagnosed between 2007 and 2022; and (II) external validation using two independent multicenter registry cohorts: 1473 Korean patients (2010-2021) and 314 Japanese patients (2008-2023). Multivariable Cox regression was performed incorporating key clinical factors, including ECOG performance status, R2-ISS stage, and frontline treatment intensity.
resultsThe MM-CI was derived from eight variables: male sex; age 60-69, 70-79, and ≥80 years; congestive heart failure, cerebrovascular disease, hepatic disease, and cancer: 1 × (Sex: Male) + 2 × (Age: 60-69 years) + 4 × (Age: 70-79 years) + 6 × (Age ≥80 years) + 2 × (Congestive heart failure: Yes) + 1 × (Cerebrovascular disease: Yes) + 1 × (Hepatic disease: Yes) + 1 × (Cancer: Yes). Risk scores stratified patients into four groups: low (0-2), intermediate-I (3-4), intermediate-II (5), and high (≥6), with corresponding median overall survival (OS) of 72.5, 43.8, 30.9, and 20.3 months, respectively. Validation analyses demonstrated superior predictive performance of the MM-CI (AUC: 0.637) compared to the conventional age-adjusted CCI (AUC: 0.613) and the concise CCI used in the IMWG frailty score (AUC: 0.569). The MM-CI remained independently prognostic after adjustment for ECOG, R2-ISS, and treatment intensity.
conclusionThe MM-CI provides a simple, objective, and clinically applicable tool for comorbidity-based risk stratification in MM. It outperforms existing models and may support treatment decisions in real-world practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.